[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diminished-ovarian-reserve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diminished-ovarian-reserve":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,52,79,105,136,157,185,216,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100641313","hippo-related-competing-endogenous-rna-cerna-network-dysregulation-and-in-vitro-fertilization-ivf-outcomes-in-women-with-diminished-ovarian-reserve-100641313",false,"NCT07658846","Hippo-Related Competing Endogenous RNA (ceRNA) Network Dysregulation and In Vitro Fertilization (IVF) Outcomes in Women With Diminished Ovarian Reserve","Investigating the Dysregulation of the Hippo-Related ceRNA Network and Its Impact on IVF Outcomes in Patients With Diminished Ovarian Reserve (DOR)","DOR-HIPPO-IVF","Inclusion Criteria:\n\n* Women undergoing In Vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI) cycles.\n* Infertility duration of at least one year\n* Primary or secondary infertility.\n\nExclusion Criteria:\n\n* Polycystic Ovary Syndrome (PCOS)\n* Endometriosis.\n* Ovarian tumors or malignancy.\n* Severe systemic diseases affecting fertility.\n* Metabolic syndrome.\n* Connective tissue disorders.\n* Hormonal therapy within the last three months.\n* Refusal to participate.","FEMALE","18 Years","40 Years",{"count":21,"type":22},70,"ESTIMATED","OBSERVATIONAL","Diminished Ovarian Reserve (DOR) is an important cause of female infertility and is associated with poor ovarian response and lower pregnancy rates during In Vitro Fertilization (IVF). The molecular mechanisms underlying impaired follicular development in DOR remain incompletely understood. Increasing evidence suggests that non-coding RNAs and components of the Hippo signaling pathway play important roles in granulosa cell proliferation, apoptosis, and follicular development.\n\nThis prospective observational cohort study aims to investigate the expression of the long non-coding RNA (lncRNA) Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), microRNA (miRNA)-181a-5p, Hippo pathway components including Yes-Associated Protein 1 (YAP1) and Connective Tissue Growth Factor (CTGF), and Insulin-Like Growth Factor 1 (IGF1) in follicular fluid-derived cells from women with DOR undergoing IVF compared with women with normal ovarian reserve. The study will also evaluate relationships among these molecular markers and IVF outcomes, including oocyte quality, number of retrieved oocytes, and embryo developmental potential.",[26,27,28],"Diminished Ovarian Reserve","Female Infertility","In Vitro Fertilization",[30,31,32,33,34,35,36,37,38],"Diminished Ovarian Reserve (DOR)","In Vitro Fertilization (IVF)","Hippo Signaling Pathway","Nuclear Paraspeckle Assembly Transcript 1 (NEAT1)","microRNA-181a-5p","Yes-Associated Protein 1 (YAP1)","Connective Tissue Growth Factor (CTGF)","Insulin-Like Growth Factor 1 (IGF1)","Follicular Fluid","NOT_YET_RECRUITING","2026-06-17",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":22},"2026-08-01",{"date":47,"type":22},"2028-10-01",{"name":49,"class":50},"Assiut University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100634153","phase-1-a-randomized-controlled-trial-of-combined-bu-shen-yi-qi-decoction-and-dehydroepiandrosterone-dhea-for-the-treatment-of-ovarian-function-decline-100634153","NCT07535983","A Randomized Controlled Trial of Combined Bu Shen Yi Qi Decoction and Dehydroepiandrosterone (DHEA) for the Treatment of Ovarian Function Decline","A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Bu Shen Yi Qi Formula With Chinese Herbal Placebo Combined With Dehydroepiandrosterone (DHEA) for the Treatment of Ovarian Dysfunction","Inclusion Criteria:\n\n1. Patients who meet both the Western medical diagnostic criteria for DOR and the Traditional Chinese Medicine (TCM) diagnostic criteria.\n2. Female patients aged 20-40 years (inclusive).\n3. No use of estrogen or progestin medications within the past three months.\n4. Voluntary participation in this study, with informed consent provided and a written informed consent form signed.\n\nExclusion Criteria:\n\n1. Concurrent reproductive endocrine, metabolic, or immune system disorders that could affect ovarian reserve or confound the evaluation of treatment efficacy, including:Polycystic ovary syndrome(PCOS),Hyperprolactinemia (a single elevated prolactin level \\> 3 times the upper limit of normal),Poorly controlled thyroid disease (thyroid-stimulating hormone \\[TSH\\] outside the normal reference range),Addison's disease,Systemic lupus erythematosus (SLE),Crohn's disease,Poorly controlled diabetes mellitus, etc.\n2. Diminished ovarian reserve (DOR) attributable to iatrogenic factors, including:Tumor-related treatments,Surgery,Radiotherapy\u002FChemotherapy,Ovarian hyperstimulation from prior in vitro fertilization (IVF) cycles\n3. Any of the following untreated or severe gynecological conditions:Unexplained irregular vaginal bleeding、Adnexal mass with a single largest diameter ≥ 4 cm、Stage III-IV endometriosis or bilateral ovarian endometriomas、Uterine fibroid(s) with a single largest diameter ≥ 4 cm、Endometrial polyp(s) with a single largest diameter \\> 1.5 cm、Planned pelvic surgery during the trial period\n4. Reduced menstrual flow (oligomenorrhea\u002Fhypomenorrhea) attributable to:Congenital uterine malformations、Uterine hypoplasia、Organic pathologies of the reproductive organs、Prior intrauterine procedures\n5. Patients with severe diseases of the cardiovascular or cerebrovascular system, liver, kidney, hematopoietic system, or other major organ systems, as well as those with psychiatric disorders or intellectual disabilities.\n6. Pregnancy or lactation.\n7. Known allergy or hypersensitivity to any component of the investigational drugs in this study.\n8. Participation in any other clinical trial within the 3 months preceding randomization.\n9. Unwillingness to sign the informed consent form for this study.",true,"20 Years",{"count":62,"type":22},74,"INTERVENTIONAL",[65,66],"PHASE1","PHASE2","The purpose of this clinical trial is to evaluate the efficacy and safety of Bushen Yiqi formula combined with dehydroepiandrosterone (DHEA) in the treatment of women with diminished ovarian reserve (DOR). The study also aims to assess the safety profile of this combined therapy.\n\nThe main questions this study aims to answer include:\n\n1. Can the Bushen Yiqi formula combined with DHEA improve ovarian reserve in women with DOR?\n2. Does the combined treatment improve hormone levels, ovarian follicle parameters, and clinical symptoms?\n3. What safety issues may occur during treatment with the Bushen Yiqi formula combined with DHEA?\n\nResearchers will compare the Bushen Yiqi formula combined with DHEA to DHEA plus placebo to determine whether the combined therapy is more effective in treating diminished ovarian reserve.\n\nParticipants will:\n\n1. Be randomly assigned to either the treatment group or the control group\n2. Receive DHEA combined with the Bushen Yiqi formula or DHEA combined with placebo for 12 weeks\n3. Undergo regular clinical assessments during the study period\n4. Have ovarian reserve markers (including AMH and antral follicle count), sex hormone levels (FSH, LH, E2, and testosterone), traditional Chinese medicine symptom scores, Kupperman menopausal index scores, inflammatory markers (CRP and IL-6), and safety indicators evaluated before and after treatment",[26],"RECRUITING","2026-06-01",{"date":72,"type":43},"2026-06-03",{"date":74,"type":43},"2025-09-01",{"date":76,"type":22},"2027-01-01",{"name":78,"class":50},"Jiangxi University of Traditional Chinese Medicine",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":87,"targetDuration":4,"studyType":63,"phases":89,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100638840","early-prevention-and-precision-management-of-female-fertility-decline-100638840","NCT07581444","Early Prevention and Precision Management of Female Fertility Decline","Development and Evaluation of a Precision Prevention Strategy for Early Female Fertility Decline Based on OvaRePred-Plus: A Multicenter Cluster Randomized Controlled Trial","OvaRePred-Plus","Inclusion Criteria:\n\n* Women aged 20-40 years\n* Diagnosed with infertility or planning assisted reproductive treatment\n* Regular menstrual cycles (21-35 days)\n* Willing to participate in a 12-week lifestyle intervention program\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Known chromosomal abnormalities or genetic disorders affecting fertility\n* History of ovarian surgery or severe ovarian damage\n* Diagnosed endocrine disorders affecting reproduction (e.g., uncontrolled thyroid disease, hyperprolactinemia)\n* Severe systemic diseases (e.g., cardiovascular, hepatic, renal diseases)\n* Current pregnancy or breastfeeding\n* Use of hormonal medications or supplements affecting ovarian function within the past 3 months\n* Participation in another clinical trial within the past 3 months",{"count":88,"type":22},384,[90],"NA","Female fertility decline has become an important public health issue in China, with a substantial proportion of women of reproductive age experiencing reduced ovarian reserve. However, effective tools for early identification and large-scale prevention of fertility impairment in the general population are still lacking.\n\nThis study aims to develop and evaluate a precision prevention strategy for early female fertility decline based on the OvaRePred-Plus model, which integrates ovarian reserve markers, lifestyle factors, and reproductive health indicators. A multicenter, cluster randomized controlled trial will be conducted across six medical centers in China, enrolling women aged 20-40 years identified as having early signs of fertility decline.\n\nParticipants will be allocated to either an intervention group receiving a comprehensive health management program (including dietary optimization, nutritional supplementation, physical activity, and sleep improvement) or a control group receiving routine clinical care. The intervention will last for 12 weeks.\n\nThe primary outcome is the change in fertility score assessed by the OvaRePred-Plus model. Secondary outcomes include changes in ovarian reserve markers (e.g., AMH), menstrual status, ultrasound parameters, and reproductive outcomes.\n\nThis study is expected to provide evidence for a scalable and cost-effective strategy for early prevention and management of female fertility decline.",[93,26,94,95],"Female Fertility Decline","Reproductive Health","Infertility Prevention","2026-05-06",{"date":98,"type":43},"2026-05-12",{"date":100,"type":22},"2026-06",{"date":102,"type":22},"2026-12",{"name":104,"class":50},"Peking University Third Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":63,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":135},"100504359","dpos-versus-gnrh-antagonist-protocol-for-oocyte-accumulation-in-low-ovarian-reserve-patients-an-rct-100504359","NCT05847283","DPOS Versus GnRH Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: An RCT","Dydrogesterone Primed Ovarian Stimulation Versus Fixed Gonadotropin Releasing Hormone Antagonist Protocol for Oocyte Accumulation in Low Ovarian Reserve Patients: A Randomized Controlled Trial","DPOS","Inclusion Criteria:\n\n* Woman aged between 18 and 37 years\n* AFC ≤ 5 and\u002For AMH ≤ 1.2 ng\u002Fml\n* Agree to perform freeze-all strategy and single frozen blastocyst embryo transfer\n\nExclusion Criteria:\n\n* Oocyte recipient\n* Indication of preimplantation genetic testing\n* Known allergic reactions to medications in the Study (progesterone products, GnRH antagonist….)\n* Basal FSH above 15mIU\u002FmL.\n* Have contraindications of ART treatment (e.g. critical or acute diseases)\n* Retrieved sperm\n* Repeated Implantation failure ( ≥ 3 failed embryo transfers with good-quality embryos)\n* Inability to comply with the study procedures.\n* Patients with a history of thyroid cancer who are on hormone replacement therapy or those diagnosed with thyroid diseases at the time of eligibility assessment","37 Years",{"count":115,"type":22},730,[90],"One of the barriers in patients with diminished ovarian reserve (DOR) is the significantly reduced number of oocytes resulting in fewer oocytes collected and embryos formed. Many ovarian stimulation strategies have been proposed to improve oocyte or embryo quantity which is oocyte accumulation could be a potential option with a comparable success rate and reasonable cost.\n\nProgestin-primed ovarian stimulation (PPOS) protocol could be suggested as an alternative method of premature Luteinizing hormone (LH) prevention in IVF. It favors segment Assisted Reproductive Technology (ART) cycles such as frozen embryo transfer (FET), oocyte donor, fertility preservation, and oocyte accumulation set. The protocol is more patient-friendly and affordable than the GnRH antagonist regimen regarding LH suppression during ovarian stimulation.\n\nMany PPOS protocols have been proposed in which the three most common agents include Dydrogesterone (DYG), Micronised Progesterone (MIP), and Medroxyprogesterone acetate (MPA). Indeed, DYG seems to have some advantages, including oral administration and safety which has been used in the treatment of threatened abortion. Initial evidence of PPOS protocol suggests that oocyte quantity and quality are comparable with other ovarian stimulation regimens. However, data related to the PPOS protocol has not been well documented, including Dydrogesteron-primed ovarian stimulation (DPOS).\n\nThere has not been an RCT with a large sample size and well-designed to provide more substantial evidence. A randomized trial to compare the effectiveness of PPOS and GnRH antagonist protocol in IVF is urgently needed.",[26],[120,121,122,123,124,125],"Progestin priming ovarian stimulation","Oocyte accumulation","Diminished ovarian reserve","GnRH antagonist","Oocyte vitrification","Dydrogesterone","2025-12-03",{"date":128,"type":43},"2025-12-10",{"date":130,"type":43},"2023-06-22",{"date":132,"type":22},"2027-12-31",{"name":134,"class":50},"Tam Anh TP. Ho Chi Minh General Hospital",2,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":51},"100602496","characterization-of-gut-and-tongue-coating-microbiota-in-patients-with-diminished-ovarian-reserve-100602496","NCT07124260","Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve","Dysbiosis of Gut-Tongue Coating Microbiota Crosstalk and Its Clinical Association With Diminished Ovarian Reserve: A Microbiome-Based Case-Control Study","CGTCMPDOR","Inclusion Criteria Developed in accordance with:\n\nThe 13th Five-Year Plan textbook Obstetrics and Gynecology (9th Edition) by China National Health Commission The 14th Five-Year Plan National Key Publication Reproductive Endocrinology (2nd Edition) Expert Consensus on Clinical Diagnosis and Treatment of Diminished Ovarian Reserve (2022)\n\nInclusion Criteria:\n\n* Female patients aged \\>20 years.\n* Diagnosis required meeting the essential criterion of AMH \\\u003C1.1 ng\u002FmL plus at least one supportive criterion: FSH \\>10 IU\u002FL, FSH\u002FLH ratio \\>3.0, or AFC \\\u003C5-7 follicles (measured on menstrual days 2-3).\n* Conscious with intact cognitive\u002Flinguistic functions to comply with study protocols.\n* Approved by Ethics Committee of Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, with written informed consent obtained.\n\nExclusion Criteria:\n\n* Female participants aged \\\u003C20 years.\n* Women in menopause, pregnancy, or lactation period.\n* Participants with comorbidities that may interfere with drug efficacy (e.g., severe chronic diseases).\n* Severe primary disorders involving cardiovascular, hepatic, renal, hematopoietic systems, or psychiatric illnesses.\n* Non-compliance with medication protocols during the study, or cases with undeterminable efficacy outcomes\u002Fincomplete data.\n* Use of sex hormone therapy within the past 3 months.\n* Diagnosis of reproductive system malignancies.\n* Gastrointestinal disorders or abnormal liver function.\n* Poor adherence to study protocols or lost to follow-up.",{"count":145,"type":22},200,"The goal of this observational study is to investigate the distinct tongue manifestation characteristics in patients with diminished ovarian reserve (DOR) compared to healthy individuals, and to clarify the features of tongue coating microbiota, gut microbiota, and their interrelationships in DOR patients. The main question it aims to answer is:\n\nWhether there are significant differences in tongue manifestations, tongue coating microbiota, and gut microbiota characteristics between DOR patients and healthy populations; Whether associations exist between tongue coating microbiota and gut microbiota in DOR patients; Whether the pathogenesis of DOR may influence estrogen metabolism through alterations in oral and gut microbiota.",[26],"2025-08-20",{"date":150,"type":43},"2025-08-26",{"date":152,"type":43},"2025-01-28",{"date":154,"type":22},"2025-12-31",{"name":156,"class":50},"Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":63,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":183,"locationsCount":184},"100577111","the-effect-of-vitc-on-ivf-outcome-of-dor-patients-100577111","NCT06794047","The Effect of VitC on IVF Outcome of DOR Patients","The Effect of Vitamin C Supplementation on Assisted Reproductive Pregnancy Outcomes in Patients With Diminished Ovarian Reserve: A Multicenter, Double-blind, Randomized Controlled Trial.","DORIVF-VC","Definition of DOR: Currently, there is no internationally unified standard for DOR. According to the latest POSEIDON criteria for diminished ovarian reserve (DOR), serum AMH \\\u003C1.20 ng\u002FmL or bilateral antral follicle count (AFC) \\\u003C5 is classified as DOR.\n\nIn this study, the participants are primarily DOR patients, with the following inclusion criteria:\n\n* Infertile women undergoing their 1st or 2nd IVF treatment\n* Diagnosed with DOR: POSEIDON criteria (AMH \\\u003C1.2 ng\u002FmL or bilateral AFC \\\u003C5) BMI between 18.5-28.0 kg\u002Fm²\n* Signed informed consent\n\nExclusion Criteria：Participants meeting any of the following criteria will be excluded from the trial:\n\n* PGT (preimplantation genetic testing) candidates\n* DOR caused by ovarian surgery, cancer radiotherapy\u002Fchemotherapy\n* Other ovulation disorders (e.g., PCOS, Cushing's syndrome, non-classic congenital adrenal hyperplasia, hyperprolactinemia) or endometriosis (chocolate cysts)\n* Severe thyroid disorders: Hyperthyroidism, Graves' disease, Hashimoto's thyroiditis\n* Acute\u002Fchronic renal insufficiency, hemodialysis, or history of severe kidney impairment\n* Infectious diseases: HIV, active hepatitis, metabolic acidosis, tuberculosis, etc.\n* Severe autoimmune diseases (e.g., rheumatoid arthritis, lupus, Crohn's disease)\n* Cardiovascular events within the past 3 months: Coronary artery disease\u002Fmyocardial infarction\u002Fclinically significant congestive heart failure；Stroke\u002Ftransient ischemic attack (TIA)；Deep vein thrombosis\u002Fpulmonary embolism；Poorly controlled hypertension (SBP ≥160 mmHg or DBP ≥90 mmHg)；Diagnosed diabetes mellitus；Coronary intervention (PCI) or coronary artery bypass grafting (CABG)；\n* Neurological disorders (e.g., dementia,Alzheimer's, Parkinson's) or use of related medications\n* Psychiatric disorders or use of antiepileptic\u002Fantidepressant drugs\n* History of cancer or radiotherapy\u002Fchemotherapy\n* Allergy to vitamin C\n* Current high-dose vitamin C supplementation (\\>500 mg\u002Fday)\n* Unwillingness to take the study-provided supplements\n* Alcohol abuse, smoking, or drug addiction\n* Participation in other clinical trials within the past month","45 Years",{"count":167,"type":22},1100,[90],"In the context of the accelerating aging population and the continuous decline in birth rates nationwide, delaying reproductive aging in women and protecting the fertility of women of childbearing age have become urgent issues and key demands that need to be addressed in the field of maternal and child health in China. The ovaries have reproductive and hormone secretion functions and are crucial throughout the female reproductive lifecycle. Women of childbearing age in China face a serious problem of diminished ovarian reserve (DOR), which can lead to infertility, failed in vitro fertilization (IVF) treatments, miscarriage, and other adverse pregnancy outcomes, severely affecting the safety of women and their offspring. For DOR patients who desire to conceive, failure to intervene and treat promptly can result in irreversible losses and impose a significant psychological burden on them. However, there are currently no clear and reliable interventions that can improve ovarian function and enhance fertility in women with DOR. Therefore, exploring new, safe, and patient-acceptable intervention strategies is urgently needed, as it may bring hope and light to women with DOR. Nutrient supplementation, especially vitamin supplementation, has received increasing attention in disease treatment due to its safety, bioavailability, and effectiveness. Previous studies have shown that vitamin C may play an important role in treating diminished ovarian reserve. However, its effects on ovarian function need to be validated in the population.\n\nBased on the above research background, this project will conduct a randomized, placebo-controlled, double-blind, multicenter trial. The study subjects will be DOR infertility patients undergoing IVF\u002FICSI treatment. The intervention group will receive oral vitamin C supplementation at a dosage of 500 mg per dose, twice a day; the control group will receive a placebo with the same dosage and method for at least three months. Patients will be followed up until delivery outcomes, comparing the IVF\u002FICSI treatment results between the vitamin C supplementation group and the placebo group. The primary endpoint of this clinical trial is the live birth rate of the IVF\u002FICSI treatment cycle. Secondary endpoints include indicators of improved ovarian reserve function, ovarian aging molecular clocks, IVF-embryo culture indicators, pregnancy rates, pregnancy complications, and neonatal conditions, thereby providing new clues and theoretical basis for clinical treatment plans for DOR patients.",[26,171],"IVF Outcomes",[173,174,175,176],"vitamin C","IVF outcomes","livebirth","diminished ovarian reserve","2025-06-11",{"date":179,"type":43},"2025-06-17",{"date":181,"type":43},"2025-03-17",{"date":132,"type":22},{"name":104,"class":50},6,{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":59,"sex":17,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":63,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":214,"locationsCount":51},"100500007","ovarian-prp-for-diminished-ovarian-reserve-100500007","NCT05790655","Ovarian PRP for Diminished Ovarian Reserve","Ovarian Platelet-Rich Plasma Injections for Diminished Ovarian Reserve Patients: A Double-Blinded Placebo-Control Trial","oPRP","Inclusion Criteria:\n\n* Clinical diagnosis of diminished ovarian reserve\n* Clinical diagnosis of poor ovarian response\n* Women age 35-42\n\nExclusion Criteria:\n\n* Clinical diagnosis of premature ovarian failure\n* Clinical diagnosis of menopause.\n* Under 35 years of age\n* Over 42 years of age","35 Years","42 Years",{"count":196,"type":22},230,[90],"This prospective double-blinded randomized placebo control study aims to determine if In Vitro Fertilization (IVF) outcomes are improved by ovarian platelet-rich plasma injections (oPRP) for women diagnosed with diminished ovarian reserve (DOR). Women with DOR notoriously have the lowest chance of pregnancy and live birth compared to age-matched peers with a normal or robust ovarian reserve.",[26],[201,202,203,204,205,206,207],"Ovarian Platelet Rich Plasma","DOR","Ovarian PRP","IVF","PRP","PGT-A","ICSI","2025-02-11",{"date":210,"type":43},"2025-02-13",{"date":212,"type":43},"2023-10-07",{"date":154,"type":22},{"name":215,"class":50},"Generation Next Fertility",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":59,"sex":17,"minAge":18,"maxAge":165,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":51},"100523521","the-correlation-between-ovarian-function-and-serum-biomarkers-100523521","NCT06096766","The Correlation Between Ovarian Function and Serum Biomarkers","Study on the Correlation Between Ovarian Function and Serum Biomarkers","Inclusion Criteria:\n\n1. The selection criteria for healthy individuals are follows.\n\n   * women aged 18-45.\n\n     * Basic FSH\\\u003C10IU\u002FL, and AMH is within the normal range.\n\n       * Regular menstruation.\n\n         * Agree and sign an informed consent form.\n2. The selection criteria for DOR patients are follows.\n\n   * women aged 18-45.\n\n     * For two consecutive menstrual cycles, 25 ≥ basal FSH ≥ 10IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n3. Selection criteria for POI patients are follows.\n\n   * 18 ≤ females aged \\\u003C40 years old.\n\n     * Two consecutive menstrual cycles with basal FSH\\>25IU\u002FL or AMH\\\u003C1.1ng\u002Fml.\n\n       * Agree and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with congenital gonadal developmental abnormalities or a family history similar to \"early menopause\".\n2. Patients with acquired organic lesions or decreased ovarian function caused by ovarian surgery.\n3. Patients who have undergone artificial cycle therapy with Western medicine or other endocrine treatments within the past three months.\n4. Patients with severe primary diseases and mental disorders such as crdiovascular, cerebrovascular, liver, kidney, and hematopoietic system.\n5. Patients during lactation or pregnancy.\n6. Patients who are allergic to the drugs used in this study or have a history of allergic reactions to traditional Chinese medicine.\n\nThose who meet any of the above 5 criteria for DOR and POI will be excluded and not included in this study. The exclusion criteria for healthy subjects are as (1), (3), (4), and (5).",{"count":224,"type":22},35,"The goal of this observational study is to find differences in serum biomarkers between ovarian function and normal individuals.",[227,26,228,229,230,231],"Premature Ovarian Insufficiency","Biomarker","Copper","Ceruloplasmin","Aging","2024-12-04",{"date":234,"type":43},"2024-12-09",{"date":236,"type":43},"2023-10-25",{"date":238,"type":22},"2025-11-11",{"name":240,"class":50},"Shi Yun",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":19,"enrollmentInfo":248,"targetDuration":4,"studyType":63,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":51},"100548850","the-effeciency-of-nmn-in-improving-ivficsi-et-pregnancy-outcomes-in-patients-with-dor-100548850","NCT06426355","The Effeciency of NMN in Improving IVF\u002FICSI-ET Pregnancy Outcomes in Patients With DOR","The Effeciency of Nicotinamide Mononucleotide (NMN) in Improving IVF\u002FICSI-ET Pregnancy Outcomes in Patients With Decreased Ovarian Reserve（DOR): a Randomized Double-blind Placebo Control Clinical Trail","Inclusion Criteria:\n\n1. Individuals who are 20 to 40 years old.\n2. At least two of the following three conditions should be met:\n\n   1. The concentrations of anti-Mullerian hormone \\\u003C 1.1 ng\u002Fml,\n   2. the values of antral follicle count was less than 7\n   3. serum concentrations of day-3 follicle-stimulating hormone (FSH)： 10 IU\u002FL ≤ FSH\\\u003C20 IU\u002FL\n3. Individuals who can insist on continuous monitoring in the outpatient clinic.\n4. Individuals who are not participating in other research projects currently or 3 months before the intervention.\n\nExclusion Criteria:\n\n1. Individuals who are during pregnant, lactation or menopause.\n2. Individuals who had non-46-XX karyotype, or attributed to known genetic etiology.\n\n   Individuals who had pelvic surgery.\n3. Cancer patients or receiving chemo\u002Fradiotherapy treatment within the past 5 years.\n4. Individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.\n5. Individuals who currently receiving weight-loss drugs or surgery or within the past 2 months.\n6. Use of medications or traditional Chinese medicine that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 3 months.\n7. Individuals who take niacin, nicotinamide, or other vitamin B3-related supplementation, or other supplementation such as coenzyme Q10, vitamin E currently or within the past 3 months.\n8. Use of antibiotics, probiotics, or prebiotics that affect the flora within the past 3 months.\n9. Individuals with severe liver diseases or kidney disease that are ineligible to participate in the study.\n10. A medical history of severe cardiovascular and cerebrovascular diseases.\n11. Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption.\n12. Individuals who drink more than 15g of alcohol per day or have a smoking habit.\n13. Individuals who need drug treatment for any mental illness such as epilepsy and depression.\n14. Individuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.\n15. Unable or unwilling to follow the study protocol.\n\nIndividuals who are during pregnant, lactation or menopause. Individuals who had non-46-XX karyotype, or attributed to known genetic etiology.\n\nIndividuals who had pelvic surgery. Cancer patients or receiving chemo\u002Fradiotherapy treatment within the past 5 years.\n\nIndividuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc.\n\nIndividuals who currently receiving weight-loss drugs or surgery or within the past 2 months.\n\nUse of medications or traditional Chinese medicine that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 3 months.\n\nIndividuals who take niacin, nicotinamide, or other vitamin B3-related supplementation, or other supplementation such as coenzyme Q10, vitamin E currently or within the past 3 months.\n\nUse of antibiotics, probiotics, or prebiotics that affect the flora within the past 3 months.\n\nIndividuals with severe liver diseases or kidney disease that are ineligible to participate in the study.\n\nA medical history of severe cardiovascular and cerebrovascular diseases. Individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption.\n\nIndividuals who drink more than 15g of alcohol per day or have a smoking habit. Individuals who need drug treatment for any mental illness such as epilepsy and depression.\n\nIndividuals who suffer from infectious diseases such as hepatitis B, active tuberculosis, AIDS, etc.\n\nUnable or unwilling to follow the study protocol.\n\n\\-",{"count":145,"type":22},[90],"The purpose of the study is to understand the effect of nicotinamide mononucleotide (NMN) on patients with diminished ovarian reserve and the outcomes of IVF\u002FICSI-ET.",[26],"2024-05-17",{"date":254,"type":43},"2024-05-23",{"date":256,"type":43},"2023-10-01",{"date":258,"type":22},"2027-02",{"name":104,"class":50}]